•Checkpoint inhibitor therapy affecting PD-L1 as treatment for advanced solid tumors.•Success in trial pembrolizumab therapy in multiresistant metastatic choriocarcinoma.•Long-term remission after pembrolizumab therapy in multiresistant choriocarcinoma.•Only six reported cases, one with comparable follow-up and outcome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253948 | PMC |
| http://dx.doi.org/10.1016/j.gore.2021.100817 | DOI Listing |
Publication Analysis
Top Keywords
multiresistant metastatic
8
pembrolizumab therapy
8
therapy multiresistant
8
long-term survival
4
survival multiresistant
4
metastatic choriocarcinoma
4
choriocarcinoma pembrolizumab
4
pembrolizumab treatment
4
treatment case
4
case report
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!